Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2014 Apr;28(2):387-401. doi: 10.1016/j.hoc.2013.11.004. Epub 2014 Jan 18.

Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Author information

1
Department of Pathology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Enders 11, Boston, MA 02115, USA.
2
Department of Pathology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Bader 124.1, Boston, MA 02115, USA. Electronic address: Mark.Fleming@childrens.harvard.edu.

Abstract

In this article, the authors discuss new approaches to treating iron overload diseases using hepcidin mimetics or by modulating endogenous hepcidin expression. In particular, the authors discuss lipid nanoparticle encapsulated siRNA and antisense oligonucleotide-mediated inhibition of TMPRSS6, an upstream regulator of hepcidin, and treatment with transferrin or hepcidin mimetics, including the recently described minihepcidins. In each case, in animal models of β-thalassemia, not only do the interventions affect iron absorption but they also act as disease-modifying agents that ameliorate the ineffective erythropoiesis.

KEYWORDS:

Hepcidin/minihepcidins; Hereditary hemochromatosis; Ineffective erythropoiesis; Iron metabolism; Lipid nanoparticle siRNA/antisense oligonucleotide; β-Thalassemia

PMID:
24589273
PMCID:
PMC3942790
DOI:
10.1016/j.hoc.2013.11.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center